Allos, AMAG Pharmaceuticals deal

Allos said an undisclosed company withdrew an offer to acquire Allos for $2.20 per share, or about $232 million. Last month, Allos said it was in negotiations with the company (see BioCentury, Sept. 26).

Allos said it continues to work toward completing its all-stock merger with hematology company AMAG. At AMAG's Oct. 7 close of $13.17, before Allos announced the offer had been withdrawn, the merger would value Allos at about $181 million, based on 105.7 million shares outstanding on Aug. 1. When the merger was first announced, it valued Allos at $258 million (see BioCentury, July 25). ...